TENAX THERAPEUTICS INC (TENX) Stock News
NASDAQ:TENX - Nasdaq - US88032L6056 - Common Stock - Currency: USD
TENX Latest News, Press Relases and Analysis
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3,...
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients...
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates...
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused...
TENX Stock Earnings: Tenax Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ:TENX) just reported results for the second quarter o...
TENX Stock Earnings: Tenax Therapeutics Beats EPS for Q2 2024
TENX stock results show that Tenax Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Why Is Tenax Therapeutics (TENX) Stock Up 29% Today?
Tenax Therapeutics stock is up on Tuesday after the company revealed an oversubscribed private placement for TENX shares.
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients...
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3,...
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenax Therapeutics (NASDAQ:TENX) just reported results for the fourth quarter o...
TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023
TENX stock results show that Tenax Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with...
Tenax Therapeutics to Present at the 36th Annual Roth Conference
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company...
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Dr. Sanjiv Shah, a renowned, global expert in the treatment of HFpEF and PH-HFpEF, will present data highlighting the use of levosimendan for the treatment...
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...
ACB Stock Alert: The $50 Million Reason Aurora Cannabis Is Up Today
Aurora Cannabis stock is rising higher on Thursday as ACB investors react to the company acquiring MedReleaf Australia for $50 million.
Why Is Disney (DIS) Stock Up 9% Today?
Disney stock is gaining on Thursday as investors in DIS shares celebrate the company's strong earnings report for the first quarter of 2024.
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
Tenax Therapeutics stock is falling on Thursday after the company announced the pricing of a public offering for TENX shares.
Tenax Therapeutics stock sinks after it prices its public offering (NASDAQ:TENX)
Tenax Therapeutics prices public offering at $5.65 per share, raising $9.04M. Shares plummet 64.24% in pre-market trade.
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting Thursday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will...